Skip to content

H.R. 4007 · 118th Congress (2023–2025)

HEAL Act of 2023

This bill requires the Department of Health and Human Services (HHS) to ensure that references in its grant programs to opioid overdose reversal agents are inclusive of any such agents that have been approved by the Food and Drug Administration (FDA).

Specifically, HHS must ensure that regulations, guidance, and other documents for grant programs that include references to opioid overdose reversal agents (e.g., naloxone) encompass any opioid overdose reversal agent that has been approved by the FDA. HHS must also update such references with respect to materials that were previously issued for State Opioid Response Grants, Tribal Opioid Response Grants, and Programs of Regional and National Significance for substance use disorder prevention.

!--tinycomments|2.1|data:application/json;base64,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-->
Show official title

To ensure references to opioid overdose reversal agents in grant programs of the Department of Health and Human Services are not limited to naloxone.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 4007’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Kelly Armstrong (R-ND-At Large) (R-ND)
Cosponsors
9 cosponsors

1 original · 8 later

3 R · 6 D

  1. Rep. Paul Tonko (D-NY-20)· Original · Jun 12, 2023
  2. Rep. Brittany Pettersen (D-CO-7)· Later · Jun 21, 2023
  3. Rep. David J. Trone (D-MD-6)· Later · Jun 30, 2023
  4. Rep. David P. Joyce (R-OH-14)· Later · Jul 24, 2023
  5. Rep. Derek Kilmer (D-WA-6)· Later · Jul 26, 2023
  6. Rep. Don Bacon (R-NE-2)· Later · Aug 4, 2023
  7. Rep. Ann M. Kuster (D-NH-2)· Later · Aug 11, 2023
  8. Rep. Michael Lawler (R-NY-17)· Later · Sep 12, 2023
  9. Rep. Chris Pappas (D-NH-1)· Later · Apr 19, 2024
Policy area
Health
Subjects
  • Drug therapy
  • Drug trafficking and controlled substances
  • Drug, alcohol, tobacco use
  • Government information and archives

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Jun 12, 2023 – Jun 16, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Jun 12, 2023
  2. HouseHealthReferred Jun 16, 2023
    1. Jun 21, 2023 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (3)
  1. HEAL Act of 2023

    Display title, Short title · Introduced in House

  2. Halting the Epidemic of Addiction and Loss Act of 2023

    Short title · Introduced in House

  3. To ensure references to opioid overdose reversal agents in grant programs of the Department of Health and Human Services are not limited to naloxone.

    Official title · Introduced in House